Literature DB >> 3484706

Mode of action of human urinary colony-stimulating factor.

Y Ishizaka, K Motoyoshi, K Hatake, M Saito, F Takaku, Y Miura.   

Abstract

Human urinary colony-stimulating factor (CSF-HU) has been highly purified using procedures containing DEAE cellulose, phenyl Sepharose CL-4B, Sephadex G-200, hydroxylapatite, and high performance liquid chromatography. The final preparation had a specific activity of 3.3 X 10(7) U/mg protein. Although the purified CSF-HU was not active on human monocyte-depleted bone marrow cells, it stimulated human peripheral blood monocytes obtained from five healthy volunteers to produce human active granulocytic colony-stimulating factor (G-CSF), which stimulated human monocyte-depleted bone marrow cells to form granulocytic colonies. The human G-CSF-producing activity of CSF-HU was not neutralized by polymyxin B, which is known to inhibit the effect of endotoxin. Newly produced G-CSF had an approximate molecular weight of 24,000 daltons as judged by chromatography on Sephadex G-150. These results indicate that CSF-HU stimulates human monocytes to produce human G-CSF in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484706

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

Review 1.  Preclinical and clinical studies with the hematopoietic colony-stimulating factors and related interleukins.

Authors:  H E Broxmeyer; S Vadhan-Raj
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 2.  Colony-stimulating factors in the pathogenesis and treatment of disease.

Authors:  D J Williamson; C G Begley
Journal:  Postgrad Med J       Date:  1987-12       Impact factor: 2.401

3.  Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection.

Authors:  T Kuhara; K Uchida; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

4.  Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP.

Authors:  Hisaharu Shikata; Yoshihiro Yakushijin; Jun Yamanouchi; Taichi Azuma; Masaki Yasukawa
Journal:  Int J Clin Oncol       Date:  2013-02-05       Impact factor: 3.402

5.  Urinary bladder carcinoma producing granulocyte colony stimulating factor (G-CSF): a case report with immunohistochemistry.

Authors:  T Ito; K Shimamura; K Shoji; A Akatsuka; Y Kiryu; N Tamaoki; Y Osamura
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Comparative effects in vivo of recombinant murine interleukin 3, natural murine colony-stimulating factor-1, and recombinant murine granulocyte-macrophage colony-stimulating factor on myelopoiesis in mice.

Authors:  H E Broxmeyer; D E Williams; S Cooper; R K Shadduck; S Gillis; A Waheed; D L Urdal; D C Bicknell
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

7.  Synergistic myelopoietic actions in vivo after administration to mice of combinations of purified natural murine colony-stimulating factor 1, recombinant murine interleukin 3, and recombinant murine granulocyte/macrophage colony-stimulating factor.

Authors:  H E Broxmeyer; D E Williams; G Hangoc; S Cooper; S Gillis; R K Shadduck; D C Bicknell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

8.  Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma.

Authors:  Marie Shimanuki; Yorihisa Imanishi; Yoichiro Sato; Nana Nakahara; Daisuke Totsuka; Emiri Sato; Sena Iguchi; Yasuo Sato; Keiko Soma; Yasutomo Araki; Seiji Shigetomi; Satoko Yoshida; Kosuke Uno; Yusuke Ogawa; Takehiro Tominaga; Yuichi Ikari; Junko Nagayama; Ayako Endo; Koshiro Miura; Takuya Tomioka; Hiroyuki Ozawa; Kaoru Ogawa
Journal:  Oncotarget       Date:  2018-04-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.